[Atrial fibrillation--epidemiologic, economic and individual burden of disease]
- PMID: 20221974
- DOI: 10.1055/s-0030-1249204
[Atrial fibrillation--epidemiologic, economic and individual burden of disease]
Abstract
Atrial fibrillation (AF) is the most frequent cardiac arrhythmia. AF affects especially the elderly. The incidence rises with increasing age to over 15% for those over 90 years old. AF is a risk factor for systemic embolism and ischemic stroke. Stroke with AF is more severe with regard to neurologic impairment. In the management of AF an anticoagulation is essential. However, only half of the patients benefit from anticoagulation in therapeutic target ranges. Costs associated with AF accrue to 660 to 924 Mio Euro in Germany with hospitalization being the major cost contributor. Management of stroke patients with AF is at 3000 Euro higher compared to those patients without AF. AF has an impact on patients' wellbeing and impairs patients' quality of life, particularly the symptomatic form. With an increasing ageing of the society it is suggested to ensure that care management for patients with AF will be optimized.
Georg Thieme Verlag KG Stuttgart New York.
Similar articles
-
Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.Curr Med Res Opin. 2009 Dec;25(12):2853-64. doi: 10.1185/03007990903196422. Curr Med Res Opin. 2009. PMID: 19916729
-
Population rates of hospitalization for atrial fibrillation/flutter in Canada.Can J Cardiol. 2004 Jul;20(9):869-76. Can J Cardiol. 2004. PMID: 15266356
-
Anticoagulation remains underused in prevention of stroke associated with atrial fibrillation: insights from two consecutive national surveys.Int J Cardiol. 2011 Nov 3;152(3):356-61. doi: 10.1016/j.ijcard.2010.08.005. Epub 2010 Sep 20. Int J Cardiol. 2011. PMID: 20851475
-
[Atrial fibrillation and thromboembolic events prevention. State of the art].Minerva Cardioangiol. 2001 Feb;49(1):1-13. Minerva Cardioangiol. 2001. PMID: 11279381 Review. Italian.
-
Antithrombotic therapies for stroke prevention in atrial fibrillation.Minerva Cardioangiol. 2004 Apr;52(2):125-39. Minerva Cardioangiol. 2004. PMID: 15194994 Review.
Cited by
-
Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation.Pharmacoeconomics. 2013 Mar;31(3):195-213. doi: 10.1007/s40273-013-0028-7. Pharmacoeconomics. 2013. PMID: 23444271 Review.
-
Improving performance of 3D speckle tracking in arterial hypertension and paroxysmal atrial fibrillation by using novel strain parameters.Sci Rep. 2019 May 14;9(1):7382. doi: 10.1038/s41598-019-43855-7. Sci Rep. 2019. PMID: 31089252 Free PMC article.
-
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin.Europace. 2016 Jul;18(7):979-86. doi: 10.1093/europace/euv412. Epub 2016 Feb 2. Europace. 2016. PMID: 26838691 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical